Single-agent ibrutinib for the treatment of mantle cell lymphoma (MCL): evaluating the link between durable response and quality of life (QoL) in the SPARK study Rule, S., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., Avivi, I., Advani, R., Le Gouill, S., Horowitz, N., Yuan, Z., Kranenburg, B., Zhuang, S. H., Deraedt, W., Rizo, A., Wildgust, W., Wang, M. WILEY-BLACKWELL. 2015: 59

View details for Web of Science ID 000353231200142